Reports on Lupus from AstraZeneca Provide New Insights (A Randomized, Placebo-controlled Phase Iii Extension Trial of the Long-term Safety and Tolerability of Anifrolumab In Active Systemic Lupus Erythematosus)

Source :: Immunotherapy Weekly. December 14, 2022, 139
Publication Year :: 2022
Abstract: 2022 DEC 14 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Data detailed on Autoimmune Diseases and Conditions - Lupus have been presented. According to news [...]

Subjects :: AstraZeneca PLC -- Product development
Medical research
Medicine, Experimental
Lupus -- Care and treatment -- Research
Systemic lupus erythematosus -- Research -- Care and treatment
Immunotherapy -- Research
Clinical trials -- Research
Pharmaceutical industry -- Product development
Health

Tools